Graft versus host disease following allogeneic bone marrow transplantation
- 31 December 1992
- journal article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 4 (5) , 571-576
- https://doi.org/10.1016/0952-7915(92)90028-d
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Thalidomide for the Treatment of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1992
- Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.The Journal of Experimental Medicine, 1992
- Cell-cell interaction in graft rejection responses: induction of anti-allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen.The Journal of Experimental Medicine, 1992
- REDUCTION IN THE SEVERITY OF GRAFT-VERSUS-HOST DISEASE AND INCREASED SURVIVAL IN ALLOGENEIC MICE BY TREATMENT WITH MONOCLONAL ANTIBODIES TO CELL ADHESION ANTIGENS LFA-lα AND MALA-2Transplantation, 1991
- PROTECTION FROM GRAFT-VERSUS-HOST DISEASE IN FULLY ALLOGENEIC CHIMERAS BY PRIOR ADMINISTRATION OF T CELL-DEPLETED SYNGENEIC BONE MARROWTransplantation, 1988
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987
- GRAFT REJECTION IN RECIPIENTS OF T-CELL-DEPLETED HLA-NONIDENTICAL MARROW TRANSPLANTS FOR LEUKEMIATransplantation, 1987
- BONE MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOBLASTIC LEUKEMIA DURING FIRST COMPLETE REMISSIONTransplantation, 1987
- Anti-T-Cell Reagents for Human Bone Marrow Transplantation: Ricin Linked to Three Monoclonal AntibodiesScience, 1983
- Graft-versus-Host Disease and Survival in Patients with Aplastic Anemia Treated by Marrow Grafts from HLA-Identical SiblingsNew England Journal of Medicine, 1983